Resident, Department of Periodontology, Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University, Seoul, Korea.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):480-7. doi: 10.1016/j.tripleo.2011.04.013. Epub 2011 Jul 20.
The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2.
Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks.
The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP.
rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.
本研究旨在确定羟磷灰石（HA）/β-磷酸三钙（β-TCP）比例为 20/80 并负载重组人骨形态发生蛋白（rhBMP-2）是否能增强新骨形成，并评估 rhBMP-2 的剂量依赖性反应。
在大鼠颅骨缺损处制备临界尺寸的骨缺损，并将不同 rhBMP-2 剂量的双相磷酸钙（BCP）加载到大鼠颅骨缺损处。让动物分别愈合 2 或 8 周。
在治疗组（所有剂量）中，愈合 2 周和 8 周后的新骨百分比明显高于对照组。在所有包含 BCP 的组中，8 周时的剩余 BCP 百分比明显低于 2 周时。
使用 BCP 载体给予 rhBMP-2 可显著诱导新骨形成。本研究未显示出剂量依赖性反应。
